Literature DB >> 24845459

Temporal evolution of human autoantibody response to cytoplasmic rods and rings structure during anti-HCV therapy with ribavirin and interferon-α.

Gerson Dierley Keppeke1, Minoru Satoh, Maria Lucia Gomes Ferraz, Edward K L Chan, Luís Eduardo C Andrade.   

Abstract

Autoantibodies to inosine monophosphate dehydrogenase-2 (IMPDH2), an enzyme involved in de novo biosynthesis of guanine nucleotides, are observed in a subset of hepatitis C virus (HCV) patients receiving interferon alpha (IFN-α) plus ribavirin. Anti-IMPDH2 antibodies display a peculiar cytoplasmic "rod/ring" (RR) pattern in IIF-HEp-2. We examined the dynamics of anti-RR autoimmune response with respect to immunoglobulin isotypes, titer, avidity, and protein targets in 80 sequential samples from 15 HCV patients (plus 12 randomly selected anti-RR-positive, totalizing 92 samples) collected over an 18-month period, including samples collected before, during, and after IFN-α + ribavirin treatment. Immunoprecipitation showed reactivity with the 55 kDa IMPDH2 protein in 12/15 patients (80 %) and 11/15 (73 %) reacted with IMPDH2 in a sandwich ELISA. During treatment, anti-IMPDH2 autoantibodies hit their highest levels after 6-12 months of treatment and decreased post-treatment, while anti-HCV antibodies levels were stable over time. Anti-IMPDH2 IgM levels increased up until the sixth month of treatment and remained stable thereafter, while IgG levels increased steadily up to the twelfth month. Both IgG and IgM decreased during the post-treatment period. IgG avidity increased steadily up to the twelfth month of treatment. In conclusion, this study showed that the temporal kinetics of IFN-α + ribavirin-induced humoral autoimmune response to IMPDH2 exhibited a considerably delayed pace of increase in antibody levels and avidity as well as in isotype class switch in comparison with a conventional humoral response to infectious agents. These unique findings uncover intriguing differences between the autoimmune response and the immune response to exogenous agents in humans.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24845459     DOI: 10.1007/s12026-014-8515-2

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  52 in total

Review 1.  ANTIBODIES.

Authors:  S COHEN
Journal:  Mod Trends Immunol       Date:  1963

Review 2.  Control systems and decision making for antibody production.

Authors:  Christopher C Goodnow; Carola G Vinuesa; Katrina L Randall; Fabienne Mackay; Robert Brink
Journal:  Nat Immunol       Date:  2010-07-20       Impact factor: 25.606

Review 3.  Genetic basis for autoantibody-production in murine models of systemic autoimmunity.

Authors:  R Kofler; F J Dixon; A N Theofilopoulos
Journal:  Contrib Microbiol Immunol       Date:  1989

4.  Two distinct cDNAs for human IMP dehydrogenase.

Authors:  Y Natsumeda; S Ohno; H Kawasaki; Y Konno; G Weber; K Suzuki
Journal:  J Biol Chem       Date:  1990-03-25       Impact factor: 5.157

5.  Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil.

Authors:  Alexander M Strasak; Arthur Y Kim; Georg M Lauer; Paulo S de Sousa; Cleber F Ginuino; Carlos A Fernandes; Carlos E Velloso; Adilson J de Almeida; Jaqueline M de Oliveira; Clara F Yoshida; Julian Schulze zur Wiesch; Gláucia Paranhos-Baccalá; Stefan Lang; Larry J Brant; Hanno Ulmer; Susanne Strohmaier; Lalit Kaltenbach; Elisabeth Lampe; Lia L Lewis-Ximenez
Journal:  BMC Infect Dis       Date:  2011-01-12       Impact factor: 3.090

Review 6.  Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases?

Authors:  Karen H Costenbader; Steffen Gay; Marta E Alarcón-Riquelme; Luca Iaccarino; Andrea Doria
Journal:  Autoimmun Rev       Date:  2011-10-25       Impact factor: 9.754

Review 7.  Genetics of systemic autoimmunity in mouse models of lupus.

Authors:  D H Kono; A N Theofilopoulos
Journal:  Int Rev Immunol       Date:  2000       Impact factor: 5.311

8.  The significance of specific IgM antibody in the diagnosis of rubella employing the immunofluorescence technique.

Authors:  S Iwakata; A J Rhodes; N A Labzoffsky
Journal:  Can Med Assoc J       Date:  1972-02-19       Impact factor: 8.262

Review 9.  Immunologic principles of allergic disease.

Authors:  Marco Averbeck; Carl Gebhardt; Frank Emmrich; Regina Treudler; Jan C Simon
Journal:  J Dtsch Dermatol Ges       Date:  2007-11       Impact factor: 5.584

10.  SDS-PAGE for ³⁵S immunoprecipitation and immunoprecipitation western blotting.

Authors:  Edward P Trieu; Ira N Targoff
Journal:  Methods Mol Biol       Date:  2012
View more
  10 in total

Review 1.  Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy.

Authors:  Gerson Dierley Keppeke; S John Calise; Edward K L Chan; Luis Eduardo C Andrade
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

2.  Autoantibodies against "rods and rings"-related IMPDH2 in hepatitis C genotype 1 and DAA therapy in a "real life" cohort.

Authors:  Werner Dammermann; Susanne Polywka; Inga Dettmann; Swantje Mindorf; Lars Komorowski; Malte Wehmeyer; Julian Schulze Zur Wiesch; Winfried Stöcker; Stefan Lüth
Journal:  Med Microbiol Immunol       Date:  2017-08-16       Impact factor: 3.402

3.  Long-term persistence of anti-rods and rings antibodies in patients with chronic hepatitis C after antiviral treatment.

Authors:  Ana Beatriz da Silva Sacerdote; Norma Arteiro Filgueira; Silvana de Barros Barreto; Andréa Dória Batista; Edmundo Pessoa Lopes
Journal:  Immunol Res       Date:  2018-10       Impact factor: 2.829

Review 4.  Anti-rods/rings: a human model of drug-induced autoantibody generation.

Authors:  S John Calise; Gerson D Keppeke; Luis E C Andrade; Edward K L Chan
Journal:  Front Immunol       Date:  2015-02-05       Impact factor: 7.561

5.  Microinjection of specific anti-IMPDH2 antibodies induces disassembly of cytoplasmic rods/rings that are primarily stationary and stable structures.

Authors:  Gerson Dierley Keppeke; Luís Eduardo C Andrade; Scott S Grieshaber; Edward K L Chan
Journal:  Cell Biosci       Date:  2015-01-05       Impact factor: 7.133

6.  Anti-rods/rings autoantibody seropositivity does not affect response to telaprevir treatment for chronic hepatitis C infection.

Authors:  S John Calise; Nicola Bizzaro; Thuy Nguyen; Danila Bassetti; Brunetta Porcelli; Paolo Almi; Giuseppina Barberio; Giampaola Pesce; Minoru Satoh; Edward K L Chan
Journal:  Auto Immun Highlights       Date:  2016-11-14

7.  Long-term antiviral hepatitis C treatment associated with Rods and Ring Cytoplasmic antibodies.

Authors:  Vasile Feldrihan; Andreea Benea; Monica Lia Junie
Journal:  Med Pharm Rep       Date:  2019-01-15

8.  The clinical value of indirect immunofluorescence for screening anti-rods and rings antibodies: A retrospective study of two centers in China.

Authors:  Jingjing Meng; Guoxiang Yang; Siting Li; Yueming Luo; Yina Bai; Chuiwen Deng; Ning Song; Mengtao Li; Xiaofeng Zeng; Chaojun Hu
Journal:  Front Immunol       Date:  2022-09-27       Impact factor: 8.786

9.  A cell-based assay for detection of anti-fibrillarin autoantibodies with performance equivalent to immunoprecipitation.

Authors:  Gerson Dierley Keppeke; Minoru Satoh; Cristiane Kayser; Pedro Matos; Tomoko Hasegawa; Shin Tanaka; Larissa Diogenes; Rogerio Quintiliano Amaral; Silvia Helena Rodrigues; Luis Eduardo Coelho Andrade
Journal:  Front Immunol       Date:  2022-09-26       Impact factor: 8.786

Review 10.  Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014-2015.

Authors:  Edward K L Chan; Jan Damoiseaux; Orlando Gabriel Carballo; Karsten Conrad; Wilson de Melo Cruvinel; Paulo Luiz Carvalho Francescantonio; Marvin J Fritzler; Ignacio Garcia-De La Torre; Manfred Herold; Tsuneyo Mimori; Minoru Satoh; Carlos A von Mühlen; Luis E C Andrade
Journal:  Front Immunol       Date:  2015-08-20       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.